Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:[1] In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China.[2]
- Difelikefalin
- Fostamatinib (trade name Tavalisse)
- Linzagolix
- Mitiglinide (Glufast)
- Remogliflozin etabonate
- Silodosin (Urief)
- Tranilast (Rizaben)